 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...1718192021222324252627...910911» |
- Efficacy and safety of KRAS p.G12C inhibitors in advanced NSCLC: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6512;
This meta-analysis underscores the favorable safety and efficacy profiles of KRAS p.G12C inhibitors after first-line progression in advanced NSCLC, despite the frequent adverse events, which were considered manageable. Further randomized controlled trials are expected to confirm these results and refine their role in subgroup populations, including STK1 and KEAP1 co-mutations, that confer even poor prognosis.
- AMG 119 / Amgen
A systematic review of CAR T-cell therapy in lung cancer: Move forward or move on? () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6461;
P1, P1/2
The best response has been PR in < 10% of reported patients; this is not encouraging, but the details of individual patients are unclear for a meta-analysis. The results of ongoing clinical trials will be important to inform the direction of future investigations.
- Lumakras (sotorasib) / Amgen
Chemotherapy versus targeted therapy in high and low NRF2 lung adenocarcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6379;
These changes were attenuated post chemotherapy. Further, high growth inhibition was observed with carboplatin treatment in NRF2low and NRF2high LUAD cells compared to sotorasib.
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6367;
However, median PFS and OS were notably shorter, likely due to the small sample size and the inclusion of pts with poor prognostic factors like oxygen use, poor ECOG status, and untreated CNS mets. The higher incidence of CRS and ICANS following C1D1 highlights the need for vigilant monitoring during initial cycles.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Real-world effectiveness of lurbinectedin in extensive stage small cell lung cancer (ES-SCLC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6343;
If the median TTD can be considered a potential surrogate for progression free survival (PFS), then we would have a PFS of 3 months which is slightly shorter in our cohort compared to 3.5 months reported by Trigo et al in their original paper. Retrospective nature of the study and lack of control group, however, limit the predictor variables.
- Prolia (denosumab) / Amgen
Comparative efficacy and safety of bisphosphonates and other bone-modifying agents in patients with bone metastases from lung cancer: A systematic review and Bayesian network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6324;
Zoledronic Acid and Ibandronate showed moderate efficacy with favorable safety profiles. These findings provide evidence-based guidance for selecting optimal BMAs and supporting clinical decision-making in this patient population.
- Imdelltra (tarlatamab-dlle) / Amgen
Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6303;
The association between presence of CNS metastatic disease, prior CNS radiation and incidence of ICANS needs to be explored further. Mayo Clinic report of tarlatamab real world outcomes and toxicity.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer
Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6078;
Half of adults and AYAs with B-ALL who received 1L treatment went on to require 3L treatment. The majority (76%) of patients requiring 3L treatment were AYAs and adults aged 41
- Chemoinduction therapy and its response in Jehovah's Witnesses with acute lymphoblastic leukemia: A systematic review. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6063;
The myelosuppressive effects of chemo-induction, in the absence of blood and blood-product transfusions, present a substantial clinical challenge, supportive agents allow us to counteract this to a considerable degree. Careful supportive management enables remission, though long-term survival remains uncertain.
- Blincyto (blinatumomab) / Astellas, Amgen
Cytokine release syndrome among acute lymphocytic leukemia adults undergoing treatment with blinatumomab in the United States. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6039;
The most common form of CRS was grade 1, while grade 2 involved an older group. Furthermore, we confirmed that CRS significantly impacted the healthcare burden among such admissions.
- Ibrance (palbociclib) / Pfizer
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5766;
P2
Additional study is warranted to confirm the efficacy of palbociclib in this pt population. Demographics and Efficacy Outcomes (N=28)
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Comprehensive clinical and genomic characterization of advanced urachal and non-urachal adenocarcinomas of the urinary tract. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5556;
Non-5-FU based chemo shows more activity in NUA, aligning genomically with urothelial cancer. The prognostic value of KRAS alterations and the role of KRAS as a promising therapeutic target in UA, genomically resembling colorectal cancer, merits further study.
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5498;
Regorafenib combined with ICIs demonstrates promising efficacy and acceptable safety in patients with advanced HCC who have progressed after lenvatinib treatment. This study provides reference data that may inform clinical treatment choices for this patient population.
- Stivarga (regorafenib) / Bayer
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter retrospective study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5473;
P=N/A
Adding ICIs to regorafenib therapy significantly improves OS in advanced HCC patients post-progression on first-line ICI treatments, highlighting the potential of regorafenib plus ICIs as an effective second-line option. These findings provide a strong foundation for further prospective clinical research.
- imatinib / Generic mfg.
Evaluating the efficacy of tyrosine kinase inhibitors and other targeted therapies in imatinib-resistant gastrointestinal stromal tumors: A comprehensive Bayesian network meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5417;
These findings provide a strong foundation for further prospective clinical research. Imatinib has transformed GIST treatment; however, resistance typically emerges within 20
- Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / HLB Bio Group
A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5369;
P1
An RP2D of 125 mg dosage of palbociclib in combination was selected to be explored in further phase II study. Clinical trial information: NCT06654297.
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Comparative outcomes of HBV-related vs. HCV-related hepatocellular carcinoma under targeted therapy: A retrospective study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5266;
HCV-related HCC patients demonstrated longer follow-up durations and better overall survival compared to HBV-related HCC patients under targeted therapy. These findings underscore the need for tailored treatment approaches to optimize outcomes for HBV and HCV patients with HCC.
- Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Outcomes of KRAS G12C inhibitors in metastatic pancreatic cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5213;
Sotorasib and Adagrasib exhibited favorable therapeutic activity in KRAS p.G12C-mutated pancreatic cancer patients with tolerable side effects. While the results are promising, the data highlights the need for further investigations to optimize clinical outcomes.
- Real world experience with immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC): 5-year single center analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5089;
Further prospective studies are warranted to validate these findings. MVA for OS in the study cohort
- Tomudex (raltitrexed) / Pfizer, AstraZeneca, Stivarga (regorafenib) / Bayer
Real-world study of anti () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5049;
The combination of anti-PD-1 drugs, regorafenib, and raltitrexed demonstrated promising antitumor efficacy and acceptable safety in patients with metastatic CRC, offering an alternative approach to optimize combination strategies in the management of refractory metastatic colorectal cancer. Clinicopathological characteristics.
- Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Toxicity profile of fruquintinib (Fruq) versus regorafenib (Rego) in refractory metastatic colorectal cancer (mCRC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5047;
Compared to Rego, Fruq showed a more favorable toxicity profile in all TRAEs except in HTN where Fruq had a higher risk. This review emphasizes the need for direct head-to-head comparisons between Fruq and Rego in experimental settings.
- Avastin (bevacizumab) / Roche
A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5035;
Regorafenib (Reg) and TAS-102 have shown promise in mCRC treatment... The results suggest that Fru-based regimens, particularly in combination with ICIs, may offer survival benefits compared to standard regimens, especially in patients without prior Bev use.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
Regorafenib and nivolumab in refractory microsatellite stable, metastatic colorectal cancer and impact of site of dominant disease. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5030;
There was 1 durable CR off all treatment and 1 PR noted in patients with lung dominant disease. Given evidence of exceptional response after exhausting standard therapies, further investigation in patients with lung dominant disease is warranted.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5015;
P3
Limitations include the inability to adjust all covariances, biases due to unobserved covariances, and lacking comparison between reg and TAS102 due to unavailable IPDs. The findings should be validated through future RWS.
- Fruzaqla (fruquintinib) / Takeda
Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5004;
P3
Furthermore, these analyses are robust with consistent results reported using IPCW and MSM. These findings support fruquintinib as a new treatment option for patients with previously treated mCRC.
- 5-fluorouracil / Generic mfg.
The addition of monoclonal antibodies to chemotherapy in metastatic early-onset colorectal cancer: A comparative effectiveness study using real-world data. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4994;
Our study did not demonstrate survival benefits of initiating first line monoclonal antibodies in stage IV eoCRC, which is likely explained by the fact that survival depends on compliance and subsequent lines of therapy. We did not have access to RAS gene status, an important predictor of treatment response.
- Lonsurf (trifluridine/tipiracil) / Otsuka
The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4992;
We did not have access to RAS gene status, an important predictor of treatment response. In the previous studies, the overall survival would increase by 6-8 months with trifluridine
- Fruzaqla (fruquintinib) / Takeda
Cardiovascular toxicity of fruquintinib in patients with colorectal and other cancers: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4977;
Our study found that Fruquintinib is associated with significant cardiovascular risks, with hypertension being the most common adverse event, while thromboembolism did not reach statistical significance. Therefore, close monitoring for treatment-related cardiovascular events should be considered in these patients.
- Fruzaqla (fruquintinib) / Takeda
Real-world experience of fruquintinib in patients with metastatic colorectal cancer: A single-center retrospective study in the United States. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4967;
The safety profile was consistent with the FRESCO-2 study, though patients with ECOG > 1 experienced greater toxicity. Efficacy appeared lower in those previously treated with regorafenib.
- Outcomes with KRAS G12C inhibitors in metastatic colorectal cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4965;
KRAS G12C inhibitors demonstrated promising efficacy in metastatic KRAS G12C mutated CRC with an acceptable toxicity profile. However, large studies with randomization are needed to consolidate these findings.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
The prognostic value of acneiform rash grade in metastatic colorectal cancer patients treated with EGFR inhibitors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4957;
Specifically, patients with higher-grade rashes had an approximately 40% reduction in the risk of both progression and death for each increase in rash grade. These findings suggest that rash grade may serve as a prognostic indicator of treatment outcomes, offering insight into patient management strategies and guiding clinical decision-making in EGFRi therapy.
- Stivarga (regorafenib) / Bayer
Comparison of the efficacy and safety of regorafenib monotherapy and regorafenib combination therapy in the third-line treatment of metastatic colorectal cancer: A real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4954;
Regorafenib alone or in combination with TAS-102 or anti-PD-1 is safe and feasible for third-line treatment of mCRC. Additional prospective large-scale studies are required to explore combination therapy.
- Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4921;
Fruquintinib sequenced after TAS-102 +/- bev may confer an OS advantage in the treatment of mCRC. However, prospective studies evaluating sequencing strategies representative of standard prescribing patterns are still needed to firmly establish optimal sequencing of fruquintinib, regorafenib, and TAS-102-based therapy.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Sex differences in toxicities among patients receiving regorafenib or trifluridine/tipiracil for refractory metastatic colorectal cancer: A subgroup analysis from the multicenter retrospective ReTrITA study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4889;
In order to enhance comprehension of toxicities associated with sex in the future, the analysis of toxicity events could represent a valuable instrument to facilitate the collection of extensive datasets, thereby enabling a more in-depth comparison of male and female patients. Furthermore, using patient-reported outcomes may help us gain a better knowledge of the impact of anticancer treatment based on sex and gender.
- Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Navigating third-line therapies: A comprehensive review of regorafenib versus fruquintinib with placebo comparator for metastatic colorectal cancer () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4878;
Regorafenib and Fruquintinib offer similar clinical benefits in refractory mCRC, but Fruquintinib may have a more favorable toxicity profile, particularly for all-grade adverse events. These findings suggest that Fruquintinib could be a preferred option based on tolerability, though both agents remain essential therapeutic options in advanced mCRC.
- Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4866;
In 20 studies, EGFRi rechallenge was given only to patients previously progressing on 5-fluoropyrimidine, oxaliplatin or irinotecan...The pooled ORR was 15% (95% CI, 9%-24%) which is numerically higher than that achieved by FDA-approved third-line agents (trifluridine/tipiracil plus bevacizumab 6.1%, fruquintinib 2%, and regorafenib 1.5%)... EGFRi rechallenge is associated with a significantly longer PFS, numerically longer OS and clinically meaningful ORR as compared with EGFRi-free systemic therapy in patients with heavily-pretreated mCRC, particularly for patients with pre-rechallenge RAS/RAF-wild type mCRC.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Trifluridine tipiracil with bevacizumab in refractory metastatic colorectal cancer with a convenient two weekly schedule: An Indian single center experience. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4865;
Two weekly regimen was better tolerated and also convenient in this heavily pre-treated population. Considering the significant dose reductions due to low counts, we would suggest studying this two weekly combination regimen at a lower starting dose of FTD-TPI in a larger study in India.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4804;
In conclusion, our study shows that administration concurrent or sequential RT and CDK4/6 inhibitors together prolonged disease-free survival and overall survival, but also increased hematologic toxicities. Since these toxicities are manageable, we frequently use RT with CDK4/6i in our clinical practice.
- ABP1019A / AB Pharma
A phase I clinical trial of ABP1019A monotherapy in patients with advanced malignant solid tumors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4786;
P1
Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1019A in phase I dose escalation study showed that this monotherapy was well tolerated, and had preliminary anti-tumor efficacy on advanced pancreatic cancer, glioma, lung and thyroid cancer, etc. A phase II exploratory study is ongoing to further verify the safety and anti-tumor efficacy of ABP1019A on 8 types of tumors including glioma, pancreatic cancer, osteosarcoma, cholangiocarcinoma, SCLC, colorectal cancer, esophageal cancer, and gastric cancer.
- ABP-1011T / AB Pharma
A phase IIa clinical trial of ABP1011T monotherapy in patients with advanced malignant solid tumors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4726;
P1/2
Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1011T in Phase IIa exploratory study showed that ABP1011T was well tolerated, and its mono-therapy showed varying degrees of tumor shrinkage in advanced sarcoma , SCLC, EC, BC, and cervical cancer that had been treated with Anlotinib and PD-1, etc. A phase IIb study of ABP1011T will be conducted to further validate the safety, tolerability and efficacy in advanced malignant solid tumors.
- Iclusig (ponatinib) / Takeda, Blincyto (blinatumomab) / Astellas, Amgen
Efficacy and safety of combination therapy of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4723;
The combination of ponatinib and blinatumomab shows promising results in achieving event-free survival, overall survival, and complete molecular response in Ph+ ALL patients, with a manageable safety profile (16% adverse effects) at 24 months. However, well-defined studies with larger sample sizes are needed for definitive conclusions.
- Imdelltra (tarlatamab-dlle) / Amgen, Rybrevant (amivantamab-vmjw) / J&J, Lazcluze (lazertinib) / J&J
Thrombotic events and mortality associated with bispecific antibodies in lung cancer: A systematic review. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4708;
However, well-defined studies with larger sample sizes are needed for definitive conclusions. Amivantamab (EGFR + MET) and tarlatamab (Delta-like ligand 3 x CD3) were used in 80% and 20% of cases for advanced non
- Meta-analysis of the cardiovascular adverse effects of bispecific antibodies in malignant hematology therapies. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4614;
This meta-analysis has identified tachycardia, cardiac arrhythmias, and hypotension as the most significant cardiac adverse events in a pooled analysis of multiple BsAbs. Practicing oncologists, cardiologists, and pharmacists need not only to be aware of these potential toxicities, but also to establish strategies for cardiac monitoring, prevention and management in order to provide quality care to cancer patients.
- ifebemtinib (IN10018) / InxMed, Opdivo (nivolumab) / Ono Pharma, BMS, Lumakras (sotorasib) / Amgen
Targeting focal adhesion kinase to mitigate hepatotoxicity induced by PD-1 inhibition with or without KRAS G12C suppression. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4597;
Practicing oncologists, cardiologists, and pharmacists need not only to be aware of these potential toxicities, but also to establish strategies for cardiac monitoring, prevention and management in order to provide quality care to cancer patients. FAK inhibition with Ifebe effectively reduces liver toxicity associated with KRAS G12C inhibition and PD-1 antibody therapy, underscoring the need for further clinical investigation.
- Ibrance (palbociclib) / Pfizer, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Tecentriq (atezolizumab) / Roche
Outcomes and prognostic factors in breast cancer patients with leptomeningeal metastasis: Insights from a retrospective analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4573;
Invasive lobular CA and TNBCA were associated with shorter survival post-LM. Multimodal treatment showed statistically nonsignificant improved survival providing a benchmark for future studies.
- Ibrance (palbociclib) / Pfizer
Health economic impact of active e-health support in patients with advanced and metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4515;
P4
In addition to extending the interval of high quality of life and SAE-free survival, AeHS by Cankado PRO-React or similar applications could provide significant intangible benefits from societal and patient perspectives. Future trials designed to detect improvements in medication adherence or time to therapy discontinuation could demonstrate further positive impacts of AeHS.
- Lumakras (sotorasib) / Amgen
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4377;
These findings position krasID as a next-generation biomarker for identifying KRASi responders, predicting treatment duration, and guiding personalized follow-on therapies for KRAS-mutated cancers. Performance of time on sotorasib classifier
- Blincyto (blinatumomab) / Astellas, Amgen, Vitrakvi (larotrectinib) / Bayer
Understanding access to novel high-cost therapies across Canada: A survey of pediatric oncology providers. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4344;
The direct costs of these therapies must be addressed to make them less prohibitive for families; however, strategies must also be developed to mitigate psychosocial and economic impacts of travelling to obtain therapies. Universal funding of these therapies, and simplified access to proton therapy centres, including the development of Canadian proton therapy facilities, would increase equitable access, ultimately improving outcomes for children with cancer.
- Ibrance (palbociclib) / Pfizer
Palbociclib plus endocrine therapy or GnRH analogs versus capecitabine or placebo for HR+/HER2- metastatic breast cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4187;
Future research directions should explore the long-term efficacy and safety of palbociclib plus ET for the treatment of metastatic breast cancer in diverse clinical settings. This review offers insights for clinical decision-making within the dynamic and advancing field of breast cancer treatment.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Factors impacting treatment with a CDK4/6i in first line metastatic HR+/HER2- breast cancer patients. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4159;
Background: The inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i), abemaciclib, palbociclib and ribociclib, are indicated for the treatment of metastatic breast cancer (mBC) patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) disease. Pts with HR+/HER2- mBC who initiated LOT 1 therapy were more likely to receive a CDK4/6i if they were between the age of 46 and 85, had metastasis to the bone, had a better performance status (ECOG 5 HR+/HER2- mBC pts who initiated LOT 1.